The Filing Desk

UroGen Pharma vs Zevra Therapeutics

UroGen Pharma URGN · Zevra Therapeutics ZVRA · Pharmaceuticals

UroGen Pharma reported revenue of $110 million in fiscal 2025, about the same as Zevra Therapeutics' $106 million in fiscal 2025. UroGen Pharma's revenue grew 21.4% in its latest year, and Zevra Therapeutics' grew 350.9%. UroGen Pharma had an operating margin of -113.7%, against -59.1% at Zevra Therapeutics. Free cash flow was −$163 million at UroGen Pharma and −$2 million at Zevra Therapeutics.

Side by side

UroGen PharmaZevra Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$110M$106M
Revenue growth21.4%350.9%
Revenue growth a year, last 5 years56.2%51.6%
Gross margin88.7%—
Operating margin−113.7%−59.1%
Net margin−139.8%78.2%
Free cash flow−$163M−$2M
Free cash flow margin−148.2%−2.3%
Return on capital—−218.8%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count12.2%23.8%
Last close$26.18$9.08
P/E at the last close—7.6×
Insider trades, last 12 monthssold $4.7 million—
Piotroski F-score2 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
UroGen PharmaZevra Therapeutics
Operating margin
Percent of revenue
UroGen PharmaZevra Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
UroGen PharmaZevra Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the UroGen Pharma and Zevra Therapeutics pages.